



I FW  
I hereby certify that this correspondence is being deposited with the United  
States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PATENT**  
Attorney Docket No.: 02307O-124010US  
Client Reference No.: 2002-235-1

On October 25, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: M. T. Davis  
Mark T. Davis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Dennis A. CARSON  
Lorenzo M. LEONI

Application No.: 10/632,711

Filed: August 1, 2003

For: NEW USES FOR INHIBITORS OF  
INOSINE MONOPHOSPHATE  
DEHYDROGENASE

Examiner: Not Yet Assigned

Art Unit: 1614

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the non-U.S. references are enclosed. In accordance with the USPTO waiver of the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, applicant has not submitted copies of the U.S. references. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Beth L. Kelly  
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
BLK:mtd  
60294099 v1



Information Disclosure Statement by Applicant (use as many sheets as necessary)				<b>Complete if Known</b>	
Application Number	10/632,711				
Filing Date	August 1, 2003				
First Named Inventor	Carson, Dennis A.				
Art Unit	1614				
Examiner Name	Not Yet Assigned				
Sheet	3	of		Attorney Docket Number	02307O-124010US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-3,097,137	07-09-1963	Beer et al.	
	AB	US 3,205,220	09-07-1965	Svoboda et al.	
	AC	US-3,880,995	04-29-1975	Jones	
	AD	US-3,991,078	11-09-1976	Witkowski et al.	
	AE	US-4,136,175	01-23-1979	Rideout	
	AF	US-4,138,547	02-06-1979	Christensen et al.	
	AG	US-4,451,648	05-29-1984	Parsons et al.	
	AH	US-4,680,285	07-14-1987	Robins	
	AI	US-4,727,069	02-23-1988	Nelson et al.	
	AJ	US-4,753,935	06-28-1988	Nelson et al.	
	AK	US-4,786,637	11-22-1988	Allison et al.	
	AL	US-4,996,237	02-26-1991	Pettit et al.	
	AM	US-5,405,837	04-11-1995	Weber	
	AN	US-5,472,947	12-05-1995	Saida et al.	
	AO	US-5,492,897	02-20-1996	Krenitsky et al.	
	AP	US-5,561,122	10-01-1996	Kamp et al.	
	AQ	US-5,571,510	11-05-1996	Nobori et al.	
	AR	US-5,747,472	05-05-1998	Krenitsky et al.	
	AS	US-5,821,236	10-13-1998	Krenitsky et al.	
	AT	US-5,840,505	11-24-1998	Carrera et al.	
	AU	US-5,942,393	08-24-1999	Nobori et al.	
	AV	US 6,162,810	12-19-2000	Carson et al.	
	AW	US-6,210,917	04-03-2000	Carson et al.	
	AX	US-6,214,571	04-10-2001	Carrera et al.	
	AY	US-6,306,874	10-23-2001	Fraley et al.	
	AZ	US-6,395,763 B1	05-28-2002	Stamos et al.	
	BA	US-2002/0082678	06-27-2002	Sirhan et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		
	BB	WO	98/40381	A1	09-17-1998	
	BC	WO	99/55663	A1	11-04-1999	
	BD	WO	00/10600	A2	03-02-2000	
	BE	WO	00/26197	A1	05-11-2000	
	BF	WO	00/33876	A1	06-15-2000	
	BG	WO	00/35865	A2	06-22-2000	
	BH	WO	00/40269	A2	07-13-2000	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/632,711
				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	4	of		Attorney Docket Number	02307O-124010US

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>				
	BI	WO	01/00622	A1	01-04-2001		<input type="checkbox"/>
	BJ	WO	01/87324	A1	11-22-2001		<input type="checkbox"/>
	BK	WO	04/12746	A3	02-12-2004		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>2</sup>
	BL	ALLISON, A.C. et al.; "Immunological Observations on Patients with Lesch-Nyhan Syndrome, and on the role of De-Novo Purine Transformation"; 1975, <u>The Lancet</u> , pp. 1179-1183.					
	BM	ALLISON, A.C. et al.; "The role of <i>de novo</i> purine synthesis in lymphocyte transformation"; 1977, <u>Ciba Found. Symp.</u> , Vol. 48, pp. 207-224.					
	BN	BEDDOWS, Clifford G. et al.; "Synthesis and reactions of 2-(5-amino-4-carbamoylimidazol-1-yl)-2-deoxy-D-glucose, an analog of a naturally occurring imidazole nucleoside"; 1975, <u>Chemical Abstracts Service</u> , 2 page abstract.					
	BO	CATAPANO, Carlo V. et al.; "GTP Depletion Induced by IMP Dehydrogenase Inhibitors Blocks RNA-Primed DNA Synthesis"; 1995, <u>Molecular Pharmacology</u> , Vol. 47, No. 5, pp. 948-955.					
	BP	CARDUCCI, Michael A. et al.; "Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics"; 2002, <u>Journal of Clinical Oncology</u> , Vol. 20, No. 8, pp. 2171-2180.					
	BQ	CHABNER, B.A. et al.; "Antineoplastic Agents"; 1996, <u>Goodman and Gilman's the Pharmacological Basis of Therapeutics</u> , Vol. 9, pp. 1243-1247.					
	BR	de BONO, Johann S. et al.; "The ErbB receptor family: a therapeutic target for cancer"; 2002, <u>Trends in Molecular Medicine</u> , Vol. 8, No. 4, pp. S19-S26.					
	BS	DHANASEKARAN, N. et al.; "G Protein-Coupled Receptor Systems Involved in Cell Growth and Oncogenesis"; 1995, <u>Endocrine Reviews</u> , Vol. 16, No. 3, pp. 259-270.					
	BT	DOWNS, Stephen M. et al.; "Induction of Mouse Oocyte Maturation in Vivo by Perturbants of Purine Metabolism"; 1987, <u>Biology of Reproduction</u> , Vol. 36, pp. 431-437.					
	BU	DRUKER, Brian J.; "ST1571 (Gleevec™) as a paradigm for cancer therapy"; 2002, <u>Trends in Molecular Medicine</u> , Vol. 8, No. 4, pp. S14-S18.					
	BV	ERLICHMAN, Charles; "Hormonal Therapies in Cancer"; 1997, <u>Principles and Practice in Oncology</u> , Vol. 5, pp. 395-405.					
	BW	FLANAGAN, Colleen A. et al.; "Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions"; 1997, <u>Reviews of Reproduction</u> , Vol. 2, pp. 113-120.					

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				<i>Application Number</i>	10/632,711
				<i>Filing Date</i>	August 1, 2003
				<i>First Named Inventor</i>	Carson, Dennis A.
				<i>Art Unit</i>	1614
				<i>Examiner Name</i>	Not Yet Assigned
Sheet	5	of		<i>Attorney Docket Number</i>	02307O-124010US

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	BX	FOREMAN, Kimberly E.; "Kaposi's sarcoma: the role of HHV-8 and HIV-1 in pathogenesis"; 2001, <u>Expert Reviews</u> , pp. 1-17.			
	BY	FUKUI, Masaru et al.; "New Antitumor Imidazole Derivative, 5-Carbamoyl-1 H-imidazol-4-yl Piperonylate, as an Inhibitor of Purine Synthesis and Its Activation by Adenine Phosphoribosyltransferase"; 1982, <u>Cancer Research</u> , Vol. 42, pp. 1098-1102.			
	BZ	GANDHI, Varsha.; "Novel Inhibitors of DNA Replication"; 1999, <u>Hematology</u> , pp. 463-469.			
	CA	GILCHRIST, Annette et al.; "Antagonists of the Receptor-G Protein Interface Block G-Coupled Signal Transduction"; 1998, <u>The Journal of Biological Chemistry</u> , Vol. 273, No. 24, pp. 14912-14919.			
	CB	GLASSOCK, Richard J.; "The treatment of IgA nephropathy: status at the end of the millennium"; 1999, <u>J. Nephrol</u> , Vol. 12, pp. 288-296.			
	CC	GREGORY, R.K. et al.; "Vinorelbine - a clinical review"; 2000, <u>British Journal of Cancer</u> , Vol. 82, No. 12, pp. 1907-1913.			
	CD	GUPTA, R.S. et al.; "Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line"; 1988, <u>Br. J. Cancer</u> , Vol. 58, pp. 441-447.			
	CE	HEALY, Dennis P.; "[28] Genetic Analysis of G Protein-Coupled Receptor Genes, 2002, <u>Methods in Enzymology</u> , Vol. 353, pp. 448-459.			
	CF	HOESSEL, Ralph et al.; "Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases"; 1999, <u>Nature Cell Biology</u> , Vol. 1, pp. 60-67.			
	CG	HUA, Xuequn Helen et al.; "Biochemical Genetic Analysis of Indanocine Resistance In Human Leukemia"; 2001, <u>Cancer Research</u> , Vol. 61, pp. 7248-7254.			
	CH	INSEL, P.; "Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout"; 1996, <u>Goodman and Gilman's the Pharmacological Basis of Therapeutics</u> , Vol. 9, pp. 647-649.			
	CI	ISHIKAWA, Hiroaki; "Mizoribine and Mycophenolate Mofetil"; 1999, <u>Current Medicinal Chemistry</u> , Vol. 6, pp. 575-597.			
	CJ	JEMAL, Ahmedin et al.; "Cancer Statistics 2002"; 2002, <u>CA Cancer J. Clin.</u> , Vol. 52, pp. 23-47.			
	CK	KARAGIRL, Nobuya et al.; "Synthesis of Pyrazofurin and its Analogues"; 1984, <u>J. Chem. Soc. Perkin Trans. 1</u> , pp. 553-560.			
	CL	KISLIUK, Roy L.; "Synergistic interactions among antifolates"; 2000, <u>Pharmacology &amp; Therapeutics</u> , Vol. 85, pp. 183-190.			
	CM	KISOR, David F. et al.; "Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies"; 2000, <u>Journal of Clinical Oncology</u> , Vol. 18, No. 5, pp. 995-1003.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/632,711
				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	6	of		Attorney Docket Number	02307O-124010US

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	CN	LEONI, Lorenzo M. et al.; "Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells"; 2000, <u>Journal of the National Cancer Institute</u> , Vol. 92, No. 3, pp. 217-224.		
	CO	MACKENZIE, Grahame et al.; "Purines, pyrimidines, and imidazoles. Part 46. Some acyclic D-arabinose imidazole and purine nucleosides"; 1977, <u>Chemical Abstracts Service</u> , 2 page abstract.		
	CP	MACKENZIE, Grahame et al.; "Synthesis of a novel acyclic D-arabinose nucleoside"; 1975, <u>Chemical Abstracts Service</u> , 2 page abstract.		
	CQ	MAJUMDAR, Alokes et al.; "IL-3 and Ribavirin Induce Differentiation and Growth Suppression During Long-Term Treatment of a Megakaryocytic Leukemia Cell Line"; 1995, <u>Journal of Cellular Physiology</u> , Vol. 165, pp. 530-537.		
	CR	MIZUNO, Kimio, et al.; "Studies on Breddinin. I: Isolation, Characterization and Biological Properties"; 1974, <u>The Journal of Antibiotics</u> , Vol. 27, No. 10, pp. 775-782.		
	CS	MORRIS, Randall E.; "Mechanisms of action of new immunosuppressive drugs"; 1996, <u>Kidney International</u> , Vol. 49, Supple. 53, pp. S26-S38.		
	CT	NAGY, Attila et al.; "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin"; 1998, <u>PNAS</u> , Vol. 95, pp. 1794-1799.		
	CU	OLAH, Edith et al.; "Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells"; 1988, <u>PNAS</u> , Vol. 85, pp. 6533-6537.		
	CV	OLAH, Edith et al.; "Molecular Mechanisms in the Antiproliferative Action of Taxol and iazofurin"; 1996, <u>Anticancer Research</u> , Vol. 16, pp. 2469-2478.		
	CW	PRAJDA, Noemi et al.; "Sequential Impact of Tiazofurin and Ribavirin on the Enzymic Program of the Bone Marrow"; 1993, <u>Cancer Research</u> , Vol. 53, pp. 5982-5986.		
	CX	PRENZEL, Norbert et al.; "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF"; 1999, <u>Nature</u> , Vol. 402, pp. 884-888.		
	CY	Roy, K.K. et al.; "Early Development of Cyclin Dependent Kinase Modulators"; 2001, <u>Current Pharmaceutical Design</u> , Vol. 7, pp. 1669-1687.		
	CZ	SEASHOLTZ, Tammy M. et al.; "Rho as a Mediator of G Protein-Coupled Receptor Signaling"; 1999, <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Vol. 55, pp. 949-956.		
	DA	SEIDENFELD, Jerome et al.; "Androgenic Regulation of 5'-Deoxy-5'-Methylthioadenosine Concentrations and Methylthioadenosine Phosphorylase Activity in Relation to Polyamine Metabolism of Rat Prostate"; 1980, <u>Biochemical and Biophysical Research Communications</u> , Vol. 95, No. 4, pp. 1861-1868.		
	DB	SEUWEN, Klaus et al.; "G Protein-Controlled Signal Transduction Pathways and the Regulation of Cell Proliferation"; 1992, <u>Advances in Cancer Research</u> , Vol. 58, pp. 75-94.		
	DC	SHAW, Leslie M. et al.; "Mycophenolate Mofetil: A Report of the Consensus Panel"; 1995, <u>Therapeutic Drug Monitoring</u> , Vol. 17, pp. 690-699.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				<i>Application Number</i>	10/632,711
				<i>Filing Date</i>	August 1, 2003
				<i>First Named Inventor</i>	Carson, Dennis A.
				<i>Art Unit</i>	1614
				<i>Examiner Name</i>	Not Yet Assigned
Sheet	7	of		<i>Attorney Docket Number</i>	023070-124010US

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	DD	SHAWYER, Laura K. et al.; "Smart Drugs: Tyrosine kinase inhibitors in cancer therapy"; 2002, <u>Cancer Cell</u> , Vol. 1, pp. 117-132.		T <sup>2</sup>
	DE	SLICHENMYER, William J. et al.; "Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases"; 2001, <u>Seminars in Oncology</u> , Vol. 28, No. 5, Suppl. 16, pp. 67-79.		
	DF	SODHI, Akrit et al.; "The Kaposi's Sarcoma-associated Herpes Virus G Protein-coupled Receptor Up-Regulates Vascular Endothelial Growth Factor Expression and Secretion through Mitogen-activated Protein Kinase and p38 Pathways Acting on Hypoxia-inducible Factor 1 $\alpha$ "; 2000, <u>Cancer Research</u> , Vol. 60, pp. 4873-4880.		
	DG	SOLLINGER, H.W. et al.; "Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients"; 1995, <u>Transplantation</u> , Vol. 60, No. 3, pp. 225-232.		
	DH	STRANGE, Philip G.; "Agonist binding to G-protein coupled receptors"; 2000, <u>British Journal of Pharmacology</u> , Vol. 129, pp. 820-821.		
	DI	THOMSON, A.W. et al.; "Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures"; 1993, <u>Transplant Immunology</u> , Vol. 1, pp. 146-150.		
	DJ	TRICOT, Guido et al.; "Tiazofurin: Biological Effects and Clinical Uses"; 1990, <u>International Journal of Cell Cloning</u> , Vol. 8, pp. 161-170.		
	DK	VALLEE, Sebastien et al.; "Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G <sub>1</sub> "; 2000, <u>European Journal of Pharmacology</u> , Vol. 4, pp. 49-62.		
	DL	WEBER, George; "Advances in Enzyme Regulation"; 1989, <u>Proceedings of the International Conference on Critical Issues in Chemotherapy</u> , Vol. 29, pp. 75-95.		
	DM	WEBER, George; "Purine and Pyrimidine Metabolism in Man VII"; 1991, <u>Advances in Experimental Medicine and Biology</u> , Vol. 309B, pp. 287-292.		
	DN	WEBER, George et al.; "Tiazofurin Down-Regulates Expression of c-Ki-ras Oncogene in a Leukemic Patient"; 1991, <u>Cancer Communications</u> , Vol. 3, No. 3, pp. 61-66.		
	DO	WOOLAM, Gerald L.; "Cancer Statistics 2000: A Benchmark for the New Century"; 2000, <u>CA Cancer J. Clin.</u> , Vol. 50, No. 7, pp. 33.		
	DP	YALOWITX, Joel. A. et al.; "Molecular Targets of Guanine Nucleotides in Deifferentiation, Proliferation and Apoptosis"; 2000, <u>Anticancer Research</u> , Vol. 20, pp. 2329-2338.		
	DQ	ZOU, Ruiming et al.; "Synthetic Approaches to the Guanosine and Xanthosine Analogues 5-Amino-3- $\beta$ -D-ribofuranosylpyrazolo[3,4-3][1,3]oxazin-7-one and 3- $\beta$ -D-Ribofuranosylpyrazolo[3,4-e][1,3]oxazine-5,7-dione and Studies of Their Antitumor Potential"; 1991, <u>J. Med. Chem.</u> , Vol. 34, pp. 1951-1959.		

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.